Johan Vekemans
Overview
Explore the profile of Johan Vekemans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
10184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pelzer P, Stuck L, Martinez L, Richards A, Acuna-Villaorduna C, Aronson N, et al.
Lancet Microbe
. 2024 Dec;
6(2):100961.
PMID: 39709975
Background: Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development....
2.
Kulkarni P, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, et al.
Hum Vaccin Immunother
. 2024 Mar;
20(1):2304974.
PMID: 38512394
AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from...
3.
White R, Fiore-Gartland A, Hanekom W, Vekemans J, Garcia-Basteiro A, Churchyard G, et al.
Lancet Respir Med
. 2024 Jan;
12(3):e7-e8.
PMID: 38272048
No abstract available.
4.
Ramasamy M, Kelly E, Seegobin S, Dargan P, Payne R, Libri V, et al.
Lancet Microbe
. 2023 Oct;
4(11):e863-e874.
PMID: 37783221
Background: This study aimed to evaluate AZD2816, a variant-updated COVID-19 vaccine expressing the full-length SARS-CoV-2 beta (B.1.351) variant spike protein that is otherwise similar to AZD1222 (ChAdOx1 nCoV-19), and AZD1222...
5.
Hill P, Cobelens F, Martinez L, Behr M, Churchyard G, Evans T, et al.
J Infect Dis
. 2023 Aug;
228(9):1150-1153.
PMID: 37607272
A new tuberculosis vaccine is a high priority. However, the classical development pathway is a major deterrent. Most tuberculosis cases arise within 2 years after Mycobacterium tuberculosis exposure, suggesting a...
6.
Nelson K, Churchyard G, Cobelens F, Hanekom W, Hill P, Lopman B, et al.
Lancet Microbe
. 2023 Jun;
4(8):e651-e656.
PMID: 37329893
Tuberculosis is the leading bacterial cause of death globally. In 2021, 10·6 million people developed symptomatic tuberculosis and 1·6 million died. Seven promising vaccine candidates that aim to prevent tuberculosis...
7.
Rangaka M, Frick M, Churchyard G, Garcia-Basteiro A, Hatherill M, Hanekom W, et al.
Lancet Respir Med
. 2023 Mar;
11(4):380-390.
PMID: 36966794
Approximately 10·6 million people worldwide develop tuberculosis each year, representing a failure in epidemic control that is accentuated by the absence of effective vaccines to prevent infection or disease in...
8.
Kulkarni P, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, et al.
EClinicalMedicine
. 2021 Dec;
42:101218.
PMID: 34870133
Background: This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at the Serum Institute of India Pvt...
9.
Asano M, Okada H, Itoh Y, Hirata H, Ishikawa K, Yoshida E, et al.
Int J Infect Dis
. 2021 Oct;
114:165-174.
PMID: 34688944
Background: Immunogenicity and safety of the AZD1222 (ChAdOx1 nCoV-19) vaccine was evaluated in Japanese adults in an ongoing phase 1/2, randomized, double-blind, parallel-group, placebo-controlled, multi-centre trial (NCT04568031). Methods: Adults (n=256,...
10.
Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S, et al.
Nat Med
. 2021 Sep;
27(11):2032-2040.
PMID: 34588689
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized...